“…Remifentanil is an easily titratable opioid, and it also combines good intraoperative hemodynamic control with early recovery of consciousness, regardless of the infused dose and length of anesthesia [9][10][11][12]. Remifentanil has the potential clinical disadvantage of further increasing postoperative sympathetic overdrive, possibly through the rapid development of acute opioid tolerance (60-90 min in volunteers) [9,12,13] or abrupt cessation of analgesia. Although the underlying mechanism is unclear, compared with longer-acting opioids, remifentanil-based anesthesia increases the risk of postoperative hypertension, the need for postoperative antihypertensive drugs, and the need for postoperative analgesics [5,6,[11][12][13].…”